Amer Khan, MD
Nephrology · Peoria, AZNPI 1609010883
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,023 of the $70,803 with a category attached, or 74.9%. AstraZeneca accounts for 84.5% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $22,732 and has fallen 77.3% since, to $5,153 in 2025. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 499 payments — averaging $141.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$60K
- Akebia Therapeutics Inc$3K
- Amgen$2K
- Vifor Pharma, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$874
- Daiichi Sankyo Inc.$605
- plus $3K from 18 others
What the payments were for
- Consulting fees$730%
- Speaking & faculty fees$53,02375%
- Travel & lodging$6,3249%
- Food & beverage$11,11416%
- Education$2700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 156 | $59,794 |
| Akebia Therapeutics Inc | 31 | $2,931 |
| Amgen(2 entities) | 51 | $2,345 |
| Vifor Pharma, Inc. | 59 | $1,050 |
| Otsuka America Pharmaceutical, Inc. | 36 | $874 |
| Daiichi Sankyo Inc. | 26 | $605 |
| Travere Therapeutics, Inc. | 15 | $488 |
| Mallinckrodt Hospital Products Inc. | 19 | $453 |
| OPKO Pharmaceuticals, LLC | 20 | $405 |
| Calliditas Therapeutics US Inc. | 14 | $317 |
| Bayer | 15 | $271 |
| GSK | 14 | $233 |
| Ardelyx, Inc. | 7 | $150 |
| Lilly USA, LLC | 7 | $147 |
| Novartis | 6 | $130 |
| Novo Nordisk | 1 | $126 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $118 |
| Aurinia Pharma U.S., Inc. | 6 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $84 |
| Alnylam Pharmaceuticals Inc. | 3 | $78 |
| Medtronic | 1 | $35 |
| Shield Therapeutics Inc | 1 | $23 |
| Strongbridge US Inc. | 1 | $17 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,803 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 173 | $160,719 |
| LokelmaSodium Zirconium Cyclosilicate | 157 | $118,601 |
| VeltassaPatiromer Calcium Sorbitex | 126 | $108,814 |
| XphozahTenapanor Hcl | 14 | $40,999 |
| KerendiaFinerenone | 31 | $23,780 |
| Sevelamer Carbonate | 59 | $6,778 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,672 |
| Labetalol Hcl | 135 | $3,541 |
| Nifedipine ErNifedipine | 101 | $2,883 |
| ProsolParenteral Amino Acid 20% No.1 | 46 | $2,823 |
| Calcitriol | 225 | $2,759 |
| Calcium Acetate | 22 | $2,318 |
| Hydralazine Hcl | 121 | $1,525 |
| Tacrolimus | 19 | $1,437 |
| Losartan Potassium | 214 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $59,794 | $279,320330 claims |
| BayerKerendia | $271 | $23,78031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Peoria
- Randy CooperPeoria$597K
- Minesh RajpalPeoria$403K
- Umar WaheedPeoria$150K
- Asan AriffPeoria$5K
- Samer Bani HaniPhoenix$54K
- Aneesha ShettyTucson$34K
- Leslie ThomasPhoenix$22K
- Alexander NimriPhoenix$21K
- Saeed ShaffiScottsdale$19K
- Jean RobeySun City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.